Moderna Inc (MRNA) - Net Assets
Based on the latest financial reports, Moderna Inc (MRNA) has net assets worth $7.41 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.49 Billion) and total liabilities ($4.08 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MRNA tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.41 Billion |
| % of Total Assets | 64.48% |
| Annual Growth Rate | N/A |
| 5-Year Change | -38.85% |
| 10-Year Change | 927.5% |
| Growth Volatility | 279990.34 |
Moderna Inc - Net Assets Trend (2014–2025)
This chart illustrates how Moderna Inc's net assets have evolved over time, based on quarterly financial data. See Moderna Inc (MRNA) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Moderna Inc (2014–2025)
The table below shows the annual net assets of Moderna Inc from 2014 to 2025. For live valuation and market cap data, see market cap of Moderna Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $8.65 Billion | -20.65% |
| 2024-12-31 | $10.90 Billion | -21.32% |
| 2023-12-31 | $13.85 Billion | -27.55% |
| 2022-12-31 | $19.12 Billion | +35.19% |
| 2021-12-31 | $14.14 Billion | +452.32% |
| 2020-12-31 | $2.56 Billion | +117.99% |
| 2019-12-31 | $1.17 Billion | -23.23% |
| 2018-12-31 | $1.53 Billion | +144.72% |
| 2017-12-31 | $625.30 Million | -25.72% |
| 2016-12-31 | $841.85 Million | +933371.20% |
| 2015-12-31 | $90.19K | +102.06% |
| 2014-12-31 | $-4.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Moderna Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 756078800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $7.22 Billion | 83.50% |
| Other Comprehensive Income | $45.00 Million | 0.52% |
| Other Components | $1.38 Billion | 15.98% |
| Total Equity | $8.65 Billion | 100.00% |
Moderna Inc Competitors by Market Cap
The table below lists competitors of Moderna Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Centrais Elétricas Brasileiras S.A. - Eletrobrás
F:L3XB
|
$19.52 Billion |
|
Gold Circuit Electronics Ltd
TW:2368
|
$19.53 Billion |
|
ASTELLAS PHARMA UNSP.ADR
F:YPHA
|
$19.55 Billion |
|
Helvetia Holding AG
SW:HELN
|
$19.58 Billion |
|
AerCap Holdings N.V
F:R1D
|
$19.49 Billion |
|
Pan American Silver Corp
TO:PAAS
|
$19.46 Billion |
|
Jardine Matheson Holdings Limited
F:H4W
|
$19.44 Billion |
|
Expeditors International of Washington, Inc.
NASDAQ:EXPD
|
$19.44 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Moderna Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 10,901,000,000 to 8,650,000,000, a change of -2,251,000,000 (-20.6%).
- Net loss of 2,822,000,000 reduced equity.
- New share issuances of 35,000,000 increased equity.
- Other comprehensive income increased equity by 55,000,000.
- Other factors increased equity by 481,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.82 Billion | -32.62% |
| Share Issuances | $35.00 Million | +0.4% |
| Other Comprehensive Income | $55.00 Million | +0.64% |
| Other Changes | $481.00 Million | +5.56% |
| Total Change | $- | -20.65% |
Book Value vs Market Value Analysis
This analysis compares Moderna Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.69x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 40414.15x to 2.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.00 | $59.75 | x |
| 2016-12-31 | $2.24 | $59.75 | x |
| 2017-12-31 | $1.66 | $59.75 | x |
| 2018-12-31 | $18.87 | $59.75 | x |
| 2019-12-31 | $3.55 | $59.75 | x |
| 2020-12-31 | $6.72 | $59.75 | x |
| 2021-12-31 | $32.82 | $59.75 | x |
| 2022-12-31 | $45.97 | $59.75 | x |
| 2023-12-31 | $36.27 | $59.75 | x |
| 2024-12-31 | $28.39 | $59.75 | x |
| 2025-12-31 | $22.24 | $59.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Moderna Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -145.16%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.43x
- Recent ROE (-32.62%) is above the historical average (-113.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | -1295.40% | 0.05x | 0.00x | $-6.04 Million |
| 2015 | -1229.21% | 0.00% | 0.00x | 2.90x | $-1.12 Million |
| 2016 | -25.68% | -199.46% | 0.08x | 1.68x | $-300.40 Million |
| 2017 | -40.93% | -124.34% | 0.19x | 1.73x | $-318.45 Million |
| 2018 | -25.14% | -314.04% | 0.06x | 1.28x | $-537.76 Million |
| 2019 | -43.75% | -1070.07% | 0.03x | 1.35x | $-631.50 Million |
| 2020 | -29.17% | -272.16% | 0.04x | 2.86x | $-1.00 Billion |
| 2021 | 86.26% | 68.80% | 0.72x | 1.74x | $10.79 Billion |
| 2022 | 43.73% | 44.30% | 0.73x | 1.35x | $6.45 Billion |
| 2023 | -34.03% | -68.84% | 0.37x | 1.33x | $-6.10 Billion |
| 2024 | -32.67% | -111.32% | 0.23x | 1.30x | $-4.65 Billion |
| 2025 | -32.62% | -145.16% | 0.16x | 1.43x | $-3.69 Billion |
Industry Comparison
This section compares Moderna Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $74,476,711
- Average return on equity (ROE) among peers: -26.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Moderna Inc (MRNA) | $7.41 Billion | 0.00% | 0.55x | $19.49 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $110.17 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-4.24 Million | 0.00% | 0.00x | $316.27 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-6.52 Million | 0.00% | 0.00x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.36 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $39.37 Million | -86.70% | 0.59x | $3.66 Billion |
About Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses incl… Read more